OpGen CEO Oliver Schacht Appears on EdisonTV to Discuss the Future of the Combined Company

preview_player
Показать описание
Oliver Schacht, CEO of OpGen, discusses the future of OpGen following its business combination with Curetis. Schacht discusses the business model, the total addressable market, addressable opportunities from current products, and more.
  1. OpGen Inc
  2. OpGen
  3. Curetis
  4. antibiotic resistance
  5. diagnostics
  6. $OPGN
Рекомендации по теме
OpGen CEO Oliver 0:20:35

OpGen CEO Oliver Schacht Appears on Infection Control Today

OpGen CEO Oliver 0:06:43

OpGen CEO Oliver Schacht Appears on EdisonTV to Discuss the Future of the Combined Company

OpGen CEO Oliver 0:19:33

OpGen CEO Oliver Schacht on OpGen’s $15m capital raise

Oliver Schacht, CEO 0:42:33

Oliver Schacht, CEO of OPGN, Speaks to StoryTrading About OpGen and Molecular Diagnostics

OpGen's Exciting Future 0:04:56

OpGen's Exciting Future Fighting Antimicrobial Resistance

F130 How Can 0:33:16

F130 How Can We Optimize the Use of Antibiotics? (Oliver Schacht, OpGen)

OpGen - Edison 0:20:41

OpGen - Edison Open House: Global Healthcare 2021

Oliver Schacht, CEO 0:03:49

Oliver Schacht, CEO Curetis was responsible for the Only German Biotech IPO in 2015

OpGen Webinar – 0:55:54

OpGen Webinar – A corporate and business update from the front lines of the fight against AMR

OpGen – executive 0:17:41

OpGen – executive interview

OpGen: Encouraging top-line 0:08:17

OpGen: Encouraging top-line data from Unyvero urinary tract infection (UTI) panel

OpGen - Leadership 0:13:16

OpGen - Leadership in the global fight against antimicrobial resistance

OpGen: Upside in 0:05:22

OpGen: Upside in the fight against superbugs?

Opgn. #Opgn #stocks 0:00:08

Opgn. #Opgn #stocks

Antimicrobial Resistance (AMR): 0:21:07

Antimicrobial Resistance (AMR): Precision Medicine & the Rise of Superbugs

OpGen - Edison 0:10:17

OpGen - Edison Open House: Global Healthcare 2022

The Unyvero Advantage 0:01:02

The Unyvero Advantage

Oliver Schacht, Curetis, 0:01:55

Oliver Schacht, Curetis, Business Angels Congress 2017

OpGen Technology Making 0:06:03

OpGen Technology Making a Difference in the Fight Against Antimicrobrial Resistance

Antibiotic Resistance Microorganisms 0:02:41

Antibiotic Resistance Microorganisms are Becoming A Global Epidemic

Dry Biochemical Analyzer 0:02:48

Dry Biochemical Analyzer POCT

Challenges of Testing 0:46:24

Challenges of Testing Panel

“The Buzz'' Show: 0:00:42

“The Buzz'' Show: OpGen, Inc. (NASDAQ: OPGN) FDA Clearance for Acuitas® AMR Gene Panel

Smart Diagnostics for 0:02:44

Smart Diagnostics for Severe Infectious Diseases

Комментарии
Автор

I'm new to this and I have questions that perhaps someone can answer. I've, over the past couple of years on the advice of my son, invested a large amount of money in Opgen. I read that good things are happening. I read about the merge. I read about work being done in other countries. Why are you not involved in working on the virus? Or are you? Why does the stock continue to drop? I'd appreciate a response from anyone---not necessarily someone involved in the company. Thank you!

margaretsquires
Автор

Sounds great but what the hell is going on with the stock

Cccc-kyvq
Автор

Opgen should not do business with China.

sonny